---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336843"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2026-08-06T12:05:22+00:00"
generated_at: "2026-08-06T12:10:35.383335+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q2 2026 net loss $18.0M; cash $153.4M; refinances debt facility

## Summary
- GAAP net loss of $18.0M ($0.13/share) vs $25.9M ($0.49/share) in Q2 2025; non-GAAP net loss $14.3M.
- Cash, equivalents and investments $153.4M; sufficient to fund operations through H1 2028.
- Refinanced $10M debt with HSBC Ventures; can draw up to additional $20M through June 2028; total facility up to $50M.
- Appointed Scott Garland as Chairman and Michael Listgarten as General Counsel.
- ASPEN-09-Breast Phase 2 topline data from 80 patients expected mid-2027; ALX2004 safety data expected 2H 2026.

## SEC filing metadata
- accession: 0001193125-26-336843
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2026-08-06T12:05:22+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312526336843/0001193125-26-336843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312526336843/alxo-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336843
- JSON: https://secwatch.observer/filing/0001193125-26-336843.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336843.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.